Jasper Therapeutics, Inc. (JSPR) Stock Analysis & Investment Frameworks
Jasper Therapeutics, Inc. (JSPR) stock analysis on Invetso. Review Jasper Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Jasper Therapeutics, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Jasper Therapeutics, Inc. Key Financial Metrics
- Market Cap: $16.63M
- Revenue: $N/A
- ROE: -618.87%
- ROIC: -1305.04%
- Dividend Yield: N/A
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Jasper Therapeutics, Inc. Investment Frameworks
Invetso analyzes Jasper Therapeutics, Inc. (JSPR) across the following frameworks:
- Jasper Therapeutics, Inc. 10Y Growth Potential
- Jasper Therapeutics, Inc. Scenario Analysis
- Jasper Therapeutics, Inc. Risks & Opportunities
- Jasper Therapeutics, Inc. Economic Moat
- Jasper Therapeutics, Inc. Business Model
- Jasper Therapeutics, Inc. Management
- Jasper Therapeutics, Inc. SWOT Analysis
- Jasper Therapeutics, Inc. Porter's 5 Forces
- Jasper Therapeutics, Inc. PESTLE Analysis
- Jasper Therapeutics, Inc. ESG Analysis